NO843872L - Ekspresjon av plasmodium falciparum polypeptider fra klonet cdna - Google Patents
Ekspresjon av plasmodium falciparum polypeptider fra klonet cdnaInfo
- Publication number
- NO843872L NO843872L NO843872A NO843872A NO843872L NO 843872 L NO843872 L NO 843872L NO 843872 A NO843872 A NO 843872A NO 843872 A NO843872 A NO 843872A NO 843872 L NO843872 L NO 843872L
- Authority
- NO
- Norway
- Prior art keywords
- falciparum
- polypeptide
- stated
- nucleotide sequence
- dna
- Prior art date
Links
- 241000223960 Plasmodium falciparum Species 0.000 title claims description 127
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 111
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 108
- 229920001184 polypeptide Polymers 0.000 title claims description 105
- 102000053602 DNA Human genes 0.000 claims description 72
- 108020004414 DNA Proteins 0.000 claims description 70
- 239000000427 antigen Substances 0.000 claims description 65
- 102000036639 antigens Human genes 0.000 claims description 65
- 108091007433 antigens Proteins 0.000 claims description 65
- 238000010367 cloning Methods 0.000 claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 239000003795 chemical substances by application Substances 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 40
- 102000004169 proteins and genes Human genes 0.000 claims description 34
- 239000002773 nucleotide Substances 0.000 claims description 31
- 125000003729 nucleotide group Chemical group 0.000 claims description 31
- 108020004511 Recombinant DNA Proteins 0.000 claims description 25
- 210000004027 cell Anatomy 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 241001515965 unidentified phage Species 0.000 claims description 14
- 101710137302 Surface antigen S Proteins 0.000 claims description 12
- 108020004999 messenger RNA Proteins 0.000 claims description 12
- HODRFAVLXIFVTR-RKDXNWHRSA-N tevenel Chemical compound NS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 HODRFAVLXIFVTR-RKDXNWHRSA-N 0.000 claims description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 11
- 230000004927 fusion Effects 0.000 claims description 11
- 230000028993 immune response Effects 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 239000003999 initiator Substances 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 6
- 230000001747 exhibiting effect Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 244000005700 microbiome Species 0.000 claims description 5
- 230000036961 partial effect Effects 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 5
- 238000012258 culturing Methods 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 description 44
- 241000588724 Escherichia coli Species 0.000 description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
- 108020001507 fusion proteins Proteins 0.000 description 19
- 102000037865 fusion proteins Human genes 0.000 description 19
- 244000045947 parasite Species 0.000 description 14
- 241000283973 Oryctolagus cuniculus Species 0.000 description 13
- 201000004792 malaria Diseases 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 239000007983 Tris buffer Substances 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 239000002585 base Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000000020 Nitrocellulose Substances 0.000 description 7
- 229920002684 Sepharose Polymers 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 229920001220 nitrocellulos Polymers 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000001320 lysogenic effect Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 102100031780 Endonuclease Human genes 0.000 description 5
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 5
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 5
- 238000010166 immunofluorescence Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 102000004594 DNA Polymerase I Human genes 0.000 description 4
- 108010017826 DNA Polymerase I Proteins 0.000 description 4
- 241000255925 Diptera Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 241000276498 Pollachius virens Species 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000003936 merozoite Anatomy 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 210000003046 sporozoite Anatomy 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241000224016 Plasmodium Species 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001460678 Napo <wasp> Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000011681 asexual reproduction Effects 0.000 description 2
- 238000013465 asexual reproduction Methods 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 210000004201 immune sera Anatomy 0.000 description 2
- 229940042743 immune sera Drugs 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229940031348 multivalent vaccine Drugs 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 150000002972 pentoses Chemical class 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 101100176927 Bacillus subtilis (strain 168) bglS gene Proteins 0.000 description 1
- 108700003860 Bacterial Genes Proteins 0.000 description 1
- 101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- -1 EcoRI Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000015336 Helminthic disease Diseases 0.000 description 1
- 101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 102100025354 Macrophage mannose receptor 1 Human genes 0.000 description 1
- 108010031099 Mannose Receptor Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100381589 Mus musculus Glb1 gene Proteins 0.000 description 1
- 101100236068 Mus musculus Lrba gene Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 101710149086 Nuclease S1 Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000963804 Plasmodiidae Species 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 108700040121 Protein Methyltransferases Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100037204 Sal-like protein 1 Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical group BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 108010092809 exonuclease Bal 31 Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000028744 lysogeny Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000012865 response to insecticide Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000001563 schizont Anatomy 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000014639 sexual reproduction Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
- F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
- F02B75/00—Other engines
- F02B75/02—Engines characterised by their cycles, e.g. six-stroke
- F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
- F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPF784383 | 1983-01-28 | ||
| AUPF978883 | 1983-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO843872L true NO843872L (no) | 1984-09-27 |
Family
ID=25642630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO843872A NO843872L (no) | 1983-01-28 | 1984-09-27 | Ekspresjon av plasmodium falciparum polypeptider fra klonet cdna |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0134799B1 (OSRAM) |
| JP (1) | JPH06225786A (OSRAM) |
| AU (1) | AU569722B2 (OSRAM) |
| DE (1) | DE3486110D1 (OSRAM) |
| DK (1) | DK467484A (OSRAM) |
| ES (1) | ES8606494A1 (OSRAM) |
| GB (1) | GB2143830B (OSRAM) |
| GR (1) | GR81750B (OSRAM) |
| IL (1) | IL70776A (OSRAM) |
| MY (1) | MY102594A (OSRAM) |
| NO (1) | NO843872L (OSRAM) |
| OA (1) | OA07823A (OSRAM) |
| PT (1) | PT78032B (OSRAM) |
| SG (1) | SG41089G (OSRAM) |
| WO (1) | WO1984002917A1 (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2145092B (en) * | 1983-01-28 | 1988-04-07 | Univ New York | Protective peptide antigen |
| EP0135108A3 (en) * | 1983-08-12 | 1988-07-13 | Rockefeller University | Nucleotide hybridization assay for protozoan parasites |
| DE3584300D1 (de) * | 1984-02-21 | 1991-11-14 | Nat Res Dev | Herstellung von malaria-impfstoffen. |
| PH25993A (en) * | 1984-02-22 | 1992-01-13 | Wellcome Found | Cloning of DNA for protozoal antigens |
| US5126264A (en) * | 1984-09-11 | 1992-06-30 | The Walter & Eliza Hall Institute Of Medical Research | The RESA and FIRA antigens of plasmodium falciparum |
| IL76338A (en) * | 1984-09-11 | 1994-08-26 | Saramane Pty Ltd | Plasmodium plasmodium immunogenic polypeptides, AND molecules encoding them, a method for preparing the polypeptides and preparations containing the polypeptide |
| CN86100979A (zh) * | 1985-02-07 | 1986-12-17 | 史密丝克莱恩贝克曼公司 | 疟疾疫苗的制备方法 |
| EP0192626B1 (en) * | 1985-02-07 | 1992-07-29 | Smithkline Beecham Corporation | Malaria vaccine |
| WO1986004922A1 (en) * | 1985-02-20 | 1986-08-28 | Memorial Sloan-Kettering Cancer Center | cDNA CODING FOR PLASMODIUM FALCIPARUM GLYCOPHORIN BINDING PROTEINS WEIGHING 130,000 DALTONS AND 155,000 DALTONS |
| IL78476A0 (en) * | 1985-04-11 | 1986-08-31 | Inst Medical W & E Hall | Highly repetitive antigens of plasmodium falciparum |
| IL79880A0 (en) * | 1985-08-29 | 1986-11-30 | Inst Medical W & E Hall | Recombinant virus |
| IL81026A0 (en) * | 1985-12-24 | 1987-03-31 | Inst Medical W & E Hall | Peptides for immunizing against plasmodium falciparum,dna molecules coding for them and compositions containing said peptides |
| KR880701243A (ko) * | 1986-03-14 | 1988-07-26 | 원본미기재 | 말라리아에 대한 보호 면역을 제공하는 폴리펩티드 |
| US5006514A (en) * | 1986-03-20 | 1991-04-09 | Sawai Pharmaceutical Co., Ltd. | α,α-trehalose trimycolates and pharmaceutical compositions |
| FR2672290B1 (fr) | 1991-02-05 | 1995-04-21 | Pasteur Institut | Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t. |
| FR2610631B1 (fr) * | 1987-02-09 | 1989-11-24 | Pasteur Institut | Molecules comportant au moins une sequence peptidique porteuse d'un ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum dans les hepatocytes, et leurs utilisations, notamment pour le diagnostic du paludisme ou dans des compositions de vaccins contre le paludisme |
| DE3741057A1 (de) * | 1987-03-18 | 1988-09-29 | Behringwerke Ag | Klonierung von malaria-spezifischen dna-sequenzen:isolierung des gens fuer das 140 kd protein |
| ZA888983B (en) * | 1987-12-01 | 1989-08-30 | Saramane Pty Ltd | Rhoptry antigen of plasmodium falciparum |
| ZA891071B (en) * | 1988-02-12 | 1990-04-25 | Saramane Pty Ltd | Rhoptry membrane antigen of plasmodium falciparum |
| GB8819209D0 (en) * | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
| US5231168A (en) * | 1988-09-16 | 1993-07-27 | Statens Seruminstitut | Malaria antigen |
| CA2011031C (en) * | 1989-03-14 | 2000-07-18 | Robert George Ridley | Plasmodium merozoite rhoptries antigen and derivatives thereof |
| GB8905857D0 (en) * | 1989-03-14 | 1989-04-26 | Hoffmann La Roche | Plasmodium merozoite rhoptries antigen |
| GB9002512D0 (en) * | 1990-02-05 | 1990-04-04 | 3I Res Expl Ltd | Polypeptides and dna encoding same |
| KR20020028385A (ko) * | 2000-10-09 | 2002-04-17 | 박제철 | 마커를 이용한 말라리아 원충에 감염된 모기 검출방법 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5434837B2 (OSRAM) * | 1972-02-08 | 1979-10-29 | ||
| DE3033776A1 (de) * | 1980-09-09 | 1982-04-22 | Behringwerke Ag, 3550 Marburg | Verfahren zur vermehrung von protozoen |
| FI64813C (fi) * | 1980-12-31 | 1984-01-10 | Ilkka Antero Palva | Foerfarande foer producering av ett utvalt aeggviteaemne och vid foerfarandet anvaenda rekombinantplasmidvektorer |
| GB2145092B (en) * | 1983-01-28 | 1988-04-07 | Univ New York | Protective peptide antigen |
| JPS57156421A (en) * | 1981-03-24 | 1982-09-27 | Nippon Koutai Kenkyusho:Kk | Malaria vaccine and its preparation |
| ZA822539B (en) * | 1981-04-15 | 1983-11-30 | Wellcome Found | Protozoal antigen |
| IL65496A (en) * | 1981-04-15 | 1985-10-31 | Wellcome Found | Protozoal antigen,its preparation and vaccine containing it |
| GB2099300B (en) * | 1981-05-21 | 1985-02-27 | Wellcome Found | Antigens from parasites of the genus plasmodium |
| EP0071705B1 (en) * | 1981-05-21 | 1989-11-23 | The Wellcome Foundation Limited | Protozoal antigen |
| EP0101505B1 (en) * | 1982-02-17 | 1987-11-04 | D'ANTONIO, Lawrence E. | Method for the purification of parasite antigenic factors |
| DE3221881A1 (de) * | 1982-06-09 | 1983-12-15 | Münchener Apparatebau Kimmel GmbH, 8012 Ottobrunn | Verfahren zur herstellung eines impfstoffs gegen parasitaere krankheitserreger |
-
1983
- 1983-01-28 AU AU23842/84A patent/AU569722B2/en not_active Ceased
-
1984
- 1984-01-25 IL IL70776A patent/IL70776A/xx not_active IP Right Cessation
- 1984-01-26 GR GR73633A patent/GR81750B/el unknown
- 1984-01-27 GB GB08424104A patent/GB2143830B/en not_active Expired
- 1984-01-27 WO PCT/AU1984/000016 patent/WO1984002917A1/en not_active Ceased
- 1984-01-27 PT PT78032A patent/PT78032B/pt unknown
- 1984-01-27 DE DE8484900598T patent/DE3486110D1/de not_active Expired - Fee Related
- 1984-01-27 ES ES529232A patent/ES8606494A1/es not_active Expired
- 1984-01-27 EP EP84900598A patent/EP0134799B1/en not_active Expired - Lifetime
- 1984-09-25 OA OA58399A patent/OA07823A/xx unknown
- 1984-09-27 NO NO843872A patent/NO843872L/no unknown
- 1984-09-28 DK DK467484A patent/DK467484A/da not_active Application Discontinuation
-
1987
- 1987-09-11 MY MYPI87001636A patent/MY102594A/en unknown
-
1989
- 1989-07-07 SG SG410/89A patent/SG41089G/en unknown
-
1993
- 1993-10-27 JP JP5268818A patent/JPH06225786A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES529232A0 (es) | 1986-04-16 |
| AU2384284A (en) | 1984-08-09 |
| WO1984002917A1 (en) | 1984-08-02 |
| EP0134799A1 (en) | 1985-03-27 |
| IL70776A0 (en) | 1984-04-30 |
| JPH06225786A (ja) | 1994-08-16 |
| SG41089G (en) | 1989-12-22 |
| OA07823A (en) | 1986-11-20 |
| EP0134799B1 (en) | 1993-03-24 |
| PT78032A (en) | 1984-02-01 |
| AU569722B2 (en) | 1988-02-18 |
| DK467484D0 (da) | 1984-09-28 |
| GB2143830A (en) | 1985-02-20 |
| IL70776A (en) | 1991-09-16 |
| EP0134799A4 (en) | 1985-07-30 |
| DK467484A (da) | 1984-09-28 |
| GR81750B (OSRAM) | 1984-12-12 |
| ES8606494A1 (es) | 1986-04-16 |
| PT78032B (en) | 1986-03-27 |
| DE3486110D1 (de) | 1993-04-29 |
| GB2143830B (en) | 1987-02-25 |
| GB8424104D0 (en) | 1984-10-31 |
| DE3486110T2 (OSRAM) | 1993-09-09 |
| MY102594A (en) | 1992-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0134799B1 (en) | Expression of plasmodium falciparum polypeptides from cloned cdna | |
| AU722138B2 (en) | Recombinant vector containing a sequence of a lipoprotein gene for the expression of nucleotide sequences | |
| Lindler et al. | Cloning of a Brucella melitensis group 3 antigen gene encoding Omp28, a protein recognized by the humoral immune response during human brucellosis | |
| US5932705A (en) | Methods and compositions for the treatment and diagnosis of shipping fever | |
| JP2701910B2 (ja) | タンパク質免疫原及び融合タンパク質の発現のための新規なベクター | |
| Lanar et al. | Identification of paramyosin as schistosome antigen recognized by intradermally vaccinated mice | |
| US5709862A (en) | Isolated protein from Eimeria useful as a cross species vaccine | |
| WO1989002924A1 (en) | Vaccines for malaria | |
| JP3037359B2 (ja) | コクシジウム症ワクチン | |
| US5635181A (en) | Recombinant anticoccidial vaccine | |
| JP3215692B2 (ja) | 組み換えコクシジウム症ワクチン | |
| JP4573773B2 (ja) | マラリア・ワクチン | |
| CA2071395A1 (en) | Coccidiosis poultry vaccine | |
| JP3450018B2 (ja) | コクシジウム症ワクチン | |
| AU636290B2 (en) | Recombinant eimeria tenella vaccines | |
| JP2001504329A (ja) | ヘリコバクター・ピロリに関連する核酸およびアミノ酸配列ならびにそのワクチン組成物 | |
| EP0153188B1 (en) | Improvements in or relating to the production of malaria vaccines | |
| CA1337269C (en) | Vaccine against brucella abortus | |
| US5879952A (en) | 43 Kd protein vaccine and method for the production thereof | |
| JPH04504422A (ja) | ワクチンおよび診断用のリケッチア抗原 | |
| WO2002072625A1 (fr) | Preparation et utilisation d'un antigene de fusion du plasmodium | |
| EP0447808A2 (en) | Expression of Plasmodium falciparum polypeptides from cloned cDNA | |
| HK118293A (en) | Expression of plasmodium falciparum polypeptides from cloned cdna | |
| JPS6314698A (ja) | 原生動物寄生虫に対するワクチン | |
| CN101298615A (zh) | 一种新的抗恶性疟原虫表位以及含有它的疫苗 |